(Q36694805)

15 August 2017

1 reference

title

Biologic therapies in rheumatology: lessons learned, future directions (English)

1 reference

15 August 2017

1 reference

John D Isaacs

3

0 references

Robert P. Kimberly

object named as

Robert Kimberly

series ordinal

2

0 references

Vibeke Strand

series ordinal

1

object named as

Vibeke Strand

1 reference

15 August 2017

publication date

1 January 2007

1 reference

Nature Reviews Drug Discovery

15 August 2017

published in

1 reference

15 August 2017

volume

6

1 reference

15 August 2017

issue

1

1 reference

15 August 2017

page(s)

75-92

1 reference

The peritoneal cavity provides a protective niche for B1 and conventional B lymphocytes during anti-CD20 immunotherapy in mice.

15 August 2017

cites work

1 reference

Contribution of transmembrane tumor necrosis factor to host defense against Mycobacterium bovis bacillus Calmette-guerin and Mycobacterium tuberculosis infections.

21 January 2018

1 reference

Case reports of heart failure after therapy with a tumor necrosis factor antagonist

21 January 2018

1 reference

Disease activity and risk of lymphoma in patients with rheumatoid arthritis: nested case-control study

21 January 2018

1 reference

Cutting edge: distinct TCR- and CD28-derived signals regulate CD95L, Bcl-xL, and the survival of primary T cells

21 January 2018

1 reference

Cytokine pathways and joint inflammation in rheumatoid arthritis

21 January 2018

1 reference

A missense single-nucleotide polymorphism in a gene encoding a protein tyrosine phosphatase (PTPN22) is associated with rheumatoid arthritis

31 March 2020

1 reference

A gene-environment interaction between smoking and shared epitope genes in HLA-DR provides a high risk of seropositive rheumatoid arthritis

31 March 2020

1 reference

A new model for an etiology of rheumatoid arthritis: smoking may trigger HLA-DR (shared epitope)-restricted immune reactions to autoantigens modified by citrullination

31 March 2020

1 reference

Drug trials. Violent reaction to monoclonal antibody therapy remains a mystery

31 March 2020

1 reference

Reprogramming the immune system for peripheral tolerance with CD4 and CD8 monoclonal antibodies

31 March 2020

1 reference

Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve-month results of a phase iib, double-blind, randomized, placebo-controlled trial

31 March 2020

1 reference

Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition

31 March 2020

1 reference

Differential effects of administration of a human anti-CD4 monoclonal antibody, HM6G, in nonhuman primates

31 March 2020

1 reference

Regulatory decision strategy for entry of a novel biological therapeutic with a clinically unmonitorable toxicity into clinical trials: pre-IND meetings and a case example

31 March 2020

1 reference

A double-blind, placebo-controlled study of anti-CD5 immunoconjugate in patients with rheumatoid arthritis. The Xoma RA Investigator Group

31 March 2020

1 reference

Regaining self-control--regulation and immunotherapy

31 March 2020

1 reference

Naturally-occurring CD4+CD25+ immunoregulatory T cells: central players in the arena of peripheral tolerance

31 March 2020

1 reference

Repeat-cycle study of high-dose intravenous 4162W94 anti-CD4 humanized monoclonal antibody in rheumatoid arthritis. A randomized placebo-controlled trial

31 March 2020

1 reference

The CAMPATH-1 antigen (CDw52)

31 March 2020

1 reference

Humanised monoclonal antibody therapy for rheumatoid arthritis

31 March 2020

1 reference

CAMPATH-1H in rheumatoid arthritis--an intravenous dose-ranging study

31 March 2020

1 reference

Treatment of active refractory rheumatoid arthritis with humanized monoclonal antibody CAMPATH-1H administered by daily subcutaneous injection

31 March 2020

1 reference

CAMPATH-1H, a humanized monoclonal antibody, in refractory rheumatoid arthritis. An intravenous dose-escalation study

31 March 2020

1 reference

Transient increase in symptoms associated with cytokine release in patients with multiple sclerosis.

31 March 2020

1 reference

Mechanism of first-dose cytokine-release syndrome by CAMPATH 1-H: involvement of CD16 (FcgammaRIII) and CD11a/CD18 (LFA-1) on NK cells

31 March 2020

1 reference

Repopulation of blood lymphocyte sub-populations in rheumatoid arthritis patients treated with the depleting humanized monoclonal antibody, CAMPATH-1H

31 March 2020

1 reference

Dysregulated lymphocyte proliferation and differentiation in patients with rheumatoid arthritis.

31 March 2020

1 reference

Interleukin-7 deficiency in rheumatoid arthritis: consequences for therapy-induced lymphopenia

31 March 2020

1 reference

Treatment of refractory rheumatoid arthritis with a chimeric anti-CD4 monoclonal antibody. Long-term followup of CD4+ T cell counts

31 March 2020

1 reference

Morbidity and mortality in rheumatoid arthritis patients with prolonged and profound therapy-induced lymphopenia

31 March 2020

1 reference

Synovial tissue response to treatment with Campath-1H

31 March 2020

1 reference

Emergence of oligoclonal T cell populations following therapeutic T cell depletion in rheumatoid arthritis

31 March 2020

1 reference

The peptide ligands mediating positive selection in the thymus control T cell survival and homeostatic proliferation in the periphery

31 March 2020

1 reference

Pulsed monoclonal antibody treatment and autoimmune thyroid disease in multiple sclerosis

31 March 2020

1 reference

Lymphocyte homeostasis following therapeutic lymphocyte depletion in multiple sclerosis.

31 March 2020

1 reference

A therapeutic human IgG4 monoclonal antibody that depletes target cells in humans

31 March 2020

1 reference

Structural motifs involved in human IgG antibody effector functions

31 March 2020

1 reference

A novel polymorphism of FcgammaRIIIa (CD16) alters receptor function and predisposes to autoimmune disease

31 March 2020

1 reference

Long-term remission of intractable systemic vasculitis with monoclonal antibody therapy

31 March 2020

1 reference

Emergence of CD52-, glycosylphosphatidylinositol-anchor-deficient lymphocytes in rheumatoid arthritis patients following Campath-1H treatment

31 March 2020

1 reference

Selective targeting of regulatory T cells with CD28 superagonists allows effective therapy of experimental autoimmune encephalomyelitis

31 March 2020

1 reference

CD28 superagonists: mode of action and therapeutic potential

31 March 2020

1 reference

Muromonab CD3: a reappraisal of its pharmacology and use as prophylaxis of solid organ transplant rejection

31 March 2020

1 reference

Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412

31 March 2020

1 reference

Rapid recovery from T lymphopenia by CD28 superagonist therapy

31 March 2020

1 reference

Clinical medicine. Accident prompts a closer look at antibody trials

31 March 2020

1 reference

Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis

31 March 2020

1 reference

B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab

31 March 2020

1 reference

Rituximab anti-B-cell therapy in systemic lupus erythematosus: pointing to the future

31 March 2020

1 reference

Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks

31 March 2020

1 reference

The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial

31 March 2020

1 reference

Do self-perpetuating B lymphocytes drive human autoimmune disease?

31 March 2020

1 reference

B cells: a fundamental role in the pathogenesis of rheumatoid arthritis?

31 March 2020

1 reference

Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis

31 March 2020

1 reference

Anti-DNA topoisomerase IIalpha autoantibodies in localized scleroderma

31 March 2020

1 reference

Regeneration of B cell subsets after transient B cell depletion using anti-CD20 antibodies in rheumatoid arthritis

31 March 2020

1 reference

Therapeutic B cell depletion and regeneration in rheumatoid arthritis: emerging patterns and paradigms

31 March 2020

1 reference

Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: an open-label trial.

31 March 2020

1 reference

Comparison of quantitative and semiquantitative indicators of joint space narrowing in subjects with knee osteoarthritis

31 March 2020

1 reference

B-cell depletion in the treatment of patients with systemic lupus erythematosus: a longitudinal analysis of 24 patients.

31 March 2020

1 reference

Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus

31 March 2020

1 reference

Epratuzumab (humanised anti-CD22 antibody) in primary Sjögren's syndrome: an open-label phase I/II study

31 March 2020

1 reference

Rituximab treatment in patients with primary Sjögren's syndrome: an open-label phase II study

31 March 2020

1 reference

Importance of cellular microenvironment and circulatory dynamics in B cell immunotherapy

31 March 2020

1 reference

The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy

31 March 2020

1 reference

BLyS and APRIL in rheumatoid arthritis

31 March 2020

1 reference

Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group

31 March 2020

1 reference

Differential effect of isotype on efficacy of anti-tumor necrosis factor alpha chimeric antibodies in experimental septic shock

31 March 2020

1 reference

Stabilization of the bioactivity of tumor necrosis factor by its soluble receptors

31 March 2020

1 reference

Cytokines and autoantibodies to cytokines

31 March 2020

1 reference

Systemic anti-tumor necrosis factor α therapy in rheumatoid arthritis down-regulates synovial tumor necrosis factor α synthesis

31 March 2020

1 reference

Pharmacogenetic investigation of the TNF/TNF-receptor system in patients with chronic active Crohn's disease treated with infliximab

31 March 2020

1 reference

Polymorphism at position -308 of the tumor necrosis factor alpha gene influences outcome of infliximab therapy in rheumatoid arthritis

31 March 2020

1 reference

The influence of genetic variation in the HLA-DRB1 and LTA-TNF regions on the response to treatment of early rheumatoid arthritis with methotrexate or etanercept

31 March 2020

1 reference

Fcgamma receptor type IIIA polymorphisms influence treatment outcomes in patients with inflammatory arthritis treated with tumor necrosis factor alpha-blocking agents

31 March 2020

1 reference

The relationship of FcgammaRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus.

31 March 2020

1 reference

Evidence that anti-tumor necrosis factor therapy with both etanercept and infliximab induces apoptosis in macrophages, but not lymphocytes, in rheumatoid arthritis joints: Extended report

31 March 2020

1 reference

Chimeric anti-TNF-α monoclonal antibody cA2 binds recombinant transmembrane TNF-α and activates immune effector functions

31 March 2020

1 reference

Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNFalpha therapy

31 March 2020

1 reference

TNF downmodulates the function of human CD4+CD25hi T-regulatory cells

31 March 2020

1 reference

Adalimumab induces apoptosis of human monocytes: a comparative study with infliximab and etanercept

31 March 2020

1 reference

Infliximab induces potent anti-inflammatory responses by outside-to-inside signals through transmembrane TNF-alpha

31 March 2020

1 reference

Binding activities of infliximab and etanercept to transmembrane tumor necrosis factor-alpha

31 March 2020

1 reference

Early effects of tumour necrosis factor alpha blockade on skin and synovial tissue in patients with active psoriasis and psoriatic arthritis

31 March 2020

1 reference

Efficacy of a novel PEGylated humanized anti-TNF fragment (CDP870) in patients with rheumatoid arthritis: a phase II double-blinded, randomized, dose-escalating trial

31 March 2020

1 reference

A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease

31 March 2020

1 reference

CDP571, a humanised monoclonal antibody to tumour necrosis factor alpha, for moderate to severe Crohn's disease: a randomised, double blind, placebo controlled trial

31 March 2020

1 reference

Down-regulation of the nonspecific and antigen-specific T cell cytokine response in ankylosing spondylitis during treatment with infliximab

31 March 2020

1 reference

Up regulation of the production of tumour necrosis factor alpha and interferon gamma by T cells in ankylosing spondylitis during treatment with etanercept

31 March 2020

1 reference

Tumor-necrosis-factor blockers: differential effects on mycobacterial immunity

31 March 2020

1 reference

Infliximab, but not etanercept, induces IgM anti-double-stranded DNA autoantibodies as main antinuclear reactivity: biologic and clinical implications in autoimmune arthritis.

31 March 2020

1 reference

Treatment with tumour necrosis factor alpha antagonists in patients with rheumatoid arthritis induces anticardiolipin antibodies

31 March 2020

1 reference

Treatment with infliximab (Remicade) when etanercept (Enbrel) has failed or vice versa: data from the STURE registry showing that switching tumour necrosis factor alpha blockers can make sense

31 March 2020

1 reference

Efficacy and safety of switching from infliximab to adalimumab: a comparative controlled study

31 March 2020

1 reference

C-reactive protein as a predictor of infliximab treatment outcome in patients with rheumatoid arthritis: defining subtypes of nonresponse and subsequent response to etanercept

31 March 2020

1 reference

A randomized controlled trial with an anti-CCL2 (anti-monocyte chemotactic protein 1) monoclonal antibody in patients with rheumatoid arthritis

31 March 2020

1 reference

Selective stimulation of T cell subsets with antibody-cytokine immune complexes.

31 March 2020

1 reference

Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial

31 March 2020

1 reference

Response to anakinra in a de novo case of neonatal-onset multisystem inflammatory disease

31 March 2020

1 reference

Rapid responses to anakinra in patients with refractory adult-onset Still's disease

31 March 2020

1 reference

Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate

31 March 2020

1 reference

Antibody engineering for therapeutics

31 March 2020

1 reference

The protection receptor for IgG catabolism is the beta2-microglobulin-containing neonatal intestinal transport receptor

31 March 2020

1 reference

The binding site for C1q on IgG

31 March 2020

1 reference

Localization of the binding site for the human high-affinity Fc receptor on IgG.

31 March 2020

1 reference

Increasing the serum persistence of an IgG fragment by random mutagenesis.

31 March 2020

1 reference

Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes

31 March 2020

1 reference

PHASE I STUDY OF AN ENGINEERED AGLYCOSYLATED HUMANIZED CD3 ANTIBODY IN RENAL TRANSPLANT REJECTION1

31 March 2020

1 reference

Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus

31 March 2020

1 reference

Complement activation by immunoglobulin does not depend solely on C1q binding

31 March 2020

1 reference

Importance of antigen specificity for complement-mediated lysis by monoclonal antibodies.

31 March 2020

1 reference

Efficient complement-mediated lysis of cells containing the CAMPATH-1 (CDw52) antigen

31 March 2020

1 reference

Comparison of the effector functions of human immunoglobulins using a matched set of chimeric antibodies.

31 March 2020

1 reference

Reshaping human antibodies for therapy

31 March 2020

1 reference

The search continues: finding who will and who will not respond to infliximab

31 March 2020

1 reference

Fcgamma receptor type IIIA is associated with rheumatoid arthritis in two distinct ethnic groups

31 March 2020

1 reference

FcgammaRIIIA-158V and rheumatoid arthritis: a confirmation study.

31 March 2020

1 reference

Increased expression of Fcgamma receptors II and III on macrophages of rheumatoid arthritis patients results in higher production of tumor necrosis factor alpha and matrix metalloproteinase.

31 March 2020

1 reference

Role of polymorphic Fc receptor Fc gammaRIIa in cytokine release and adverse effects of murine IgG1 anti-CD3/T cell receptor antibody (WT31)

31 March 2020

1 reference

IgG receptor polymorphisms: risk factors for disease

31 March 2020

1 reference

Immune responses to therapeutic proteins in humans--clinical significance, assessment and prediction

31 March 2020

1 reference

Treatment of rheumatoid arthritis with monoclonal CD4 antibody M-T151. Clinical results and immunopharmacologic effects in an open study, including repeated administration

31 March 2020

1 reference

A simple method for measuring patient anti-globulin responses against isotypic or idiotypic determinants

31 March 2020

1 reference

Immune response to a recombinant human TNFR55-IgG1 fusion protein: auto-antibodies in rheumatoid arthritis (RA) and multiple sclerosis (MS) patients have neither neutralizing nor agonist activities

31 March 2020

1 reference

Strategies for detection, measurement and characterization of unwanted antibodies induced by therapeutic biologicals

31 March 2020

1 reference

The incidence and management of infusion reactions to infliximab: a large center experience

31 March 2020

1 reference

Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis

31 March 2020

1 reference

Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial

31 March 2020

1 reference

Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial

31 March 2020

1 reference

Population pharmacokinetics of rituximab (anti-CD20 monoclonal antibody) in rheumatoid arthritis patients during a phase II clinical trial

31 March 2020

1 reference

Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent

31 March 2020

1 reference

Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management

31 March 2020

1 reference

Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy.

31 March 2020

1 reference

Role of TNF/TNFR in autoimmunity: specific TNF receptor blockade may be advantageous to anti-TNF treatments

31 March 2020

1 reference

Transmembrane TNF is sufficient to initiate cell migration and granuloma formation and provide acute, but not long-term, control of Mycobacterium tuberculosis infection

31 March 2020

1 reference

Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti–tumor necrosis factor therapy: Results from the British Society for Rheumatology Biologics Register

31 March 2020

1 reference

Chronic exposure to tumor necrosis factor (TNF) in vitro impairs the activation of T cells through the T cell receptor/CD3 complex; reversal in vivo by anti-TNF antibodies in patients with rheumatoid arthritis

31 March 2020

1 reference

Chronic tumor necrosis factor alters T cell responses by attenuating T cell receptor signaling

31 March 2020

1 reference

Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides

31 March 2020

1 reference

Demyelinating and neurologic events reported in association with tumor necrosis factor alpha antagonism: by what mechanisms could tumor necrosis factor alpha antagonists improve rheumatoid arthritis but exacerbate multiple sclerosis?

31 March 2020

1 reference

Functional Genomic Analysis of Remyelination Reveals Importance of Inflammation in Oligodendrocyte Regeneration

31 March 2020

1 reference

Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failu

31 March 2020

1 reference

Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL).

31 March 2020

1 reference

Anti-tumor necrosis factor-alpha treatment improves endothelial function in patients with rheumatoid arthritis

31 March 2020

1 reference

Heart failure in rheumatoid arthritis: rates, predictors, and the effect of anti-tumor necrosis factor therapy

31 March 2020

1 reference

Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists

31 March 2020

1 reference

Treatment of systemic lupus erythematosus by inhibition of T cell costimulation with anti-CD154: a randomized, double-blind, placebo-controlled trial

31 March 2020

1 reference

A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis

31 March 2020

1 reference

Etanercept plus standard therapy for Wegener's granulomatosis

31 March 2020

1 reference

Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists

31 March 2020

1 reference

Antibody humanization: a case of the 'Emperor's new clothes'?

31 March 2020

1 reference

Tolerance to rat monoclonal antibodies. Implications for serotherapy

31 March 2020

1 reference

A kinetic enzyme immunoassay for the quantitation of antibodies to a humanized monoclonal antibody in human serum.

31 March 2020

1 reference

Pure red-cell aplasia due to anti-erythropoietin antibodies

31 March 2020

1 reference

Effects of administration of an anti-CD5 plus immunoconjugate in rheumatoid arthritis. Results of two phase II studies. The CD5 Plus Rheumatoid Arthritis Investigators Group

31 March 2020

1 reference

Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's Disease

31 March 2020

1 reference

A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group.

31 March 2020

1 reference

Infliximab for the treatment of fistulas in patients with Crohn's disease

31 March 2020

1 reference

Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease.

31 March 2020

1 reference

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

31 March 2020

1 reference

Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis

31 March 2020

1 reference

Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells

31 March 2020

1 reference

Interleukin-15 mediates T cell-dependent regulation of tumor necrosis factor-α production in rheumatoid arthritis

31 March 2020

1 reference

Lymphotoxin beta-mediated stimulation of synoviocytes in rheumatoid arthritis

31 March 2020

1 reference

Evolving concepts of rheumatoid arthritis

31 March 2020

1 reference

Monoclonal anti-CD4 in arthritis

31 March 2020

1 reference

Anti-CD4 antibody treatment of patients with rheumatoid arthritis: I. Effect on clinical course and circulating T cells

31 March 2020

1 reference

Immunological effects of high dose administration of anti-CD4 antibody in rheumatoid arthritis patients.

31 March 2020

1 reference

Treatment of rheumatoid arthritis with an anti-CD4 monoclonal antibody

31 March 2020

1 reference

Human anti-mouse antibody response induced by anti-CD4 monoclonal antibody therapy in patients with rheumatoid arthritis

31 March 2020

1 reference

Double-blind, placebo-controlled multicenter trial using chimeric monoclonal anti-CD4 antibody, cM-T412, in rheumatoid arthritis patients receiving concomitant methotrexate

31 March 2020

1 reference

A randomized, double‐blind, placebo‐controlled study of cd4 monoclonal antibody therapy in early rheumatoid arthritis

31 March 2020

1 reference

The pharmacokinetics and human anti-mouse antibody response in rheumatoid arthritis patients treated with a chimeric anti-CD4 monoclonal antibody

31 March 2020

1 reference

Percentage of anti-CD4 monoclonal antibody-coated lymphocytes in the rheumatoid joint is associated with clinical improvement. Implications for the development of immunotherapeutic dosing regimens

31 March 2020

1 reference

Antibody-mediated stripping of CD4 from lymphocyte cell surface in patients with rheumatoid arthritis

31 March 2020

1 reference

Humanized anti-CD4 monoclonal antibody therapy of autoimmune and inflammatory disease

31 March 2020

1 reference

Pharmacokinetic, pharmacodynamic and clinical effects of a humanized IgG1 anti-CD4 monoclonal antibody in the peripheral blood and synovial fluid of rheumatoid arthritis patients

31 March 2020

1 reference

Erythropoietic response to anemia in chronic hepatitis C patients receiving combination pegylated interferon/ribavirin

31 March 2020

1 reference

Continuous cultures of fused cells secreting antibody of predefined specificity

31 March 2020

1 reference

Antimurine antibody formation following OKT3 therapy

31 March 2020

1 reference

inferred from DOI database lookup

7 January 2021

based on heuristic

Human antiglobulin response to foreign antibodies: therapeutic benefit?

1 reference

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/NRD2196

1 reference

15 August 2017

1 reference